Adaptive Biotechnologies
ADPT
26.28
-0.62
-2.30%
Adaptive Biotechnologies
US · ADPT
#2184 by market cap
Listed 2019
26.28
-0.62
-2.30%
Live - 5344 symbols - heartbeat 468s ago
· 2026-10-08 07:30
Pre-market
25.80
-1.83%
After-hours
26.28
0.00%
Overnight
26.15
-0.49%
- Market cap
- 4.19B
- P/E (TTM)i
- -65.70
- P/Bi
- 29.36
- EPSi
- -0.39
- Div yieldi
- 0.00%
- 52W posi
- 76%
Reader sentiment
Are you bullish or bearish on ADPT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 99.44% -0.01pp
- Institutions
- 363 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund66.82%
Hedge Fund26.20%
Individual/Insider2.58%
Private Company2.34%
Public Company1.94%
Insurance Company0.82%
VC/PE Fund0.76%
Government Pension Fund0.32%
Bank/Investment Bank0.16%
Top holders as of 2026-06-30
Viking Global Investors LP
18.79% · 29.99M sh
BlackRock
9.49% · 15.14M sh
Vanguard Capital Management, LLC
4.60% · 7.34M sh
Wellington Management Group
3.70% · 5.91M sh
Vanguard Portfolio Management, LLC
3.43% · 5.48M sh
D. E. Shaw & Co., L.P.
2.90% · 4.63M sh
T. Rowe Price Group, Inc.
2.79% · 4.44M sh
Westfield Capital Management Company, L.P.
2.67% · 4.27M sh
Geode Capital Management, LLC
2.28% · 3.64M sh
State Street Global Advisors
2.17% · 3.46M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 0 buys · 50 sells
| Name | Role | Stake |
|---|---|---|
| Viking Global Investors LP | -- | 18.79% |
| Chad Robins | Chairperson & CEO | 0.95% |
| Harlan Robins | Co-Founder & CSO | 0.51% |
| Susan Bobulsky | Senior Vice President of Diagnostics - ClonoSEQ | 0.25% |
| Julie Rubinstein | President | 0.24% |
| Kyle Piskel | VP & Principal Accounting Officer | 0.16% |
| Francis Lo | Chief Human Resources Officer | 0.14% |
| Sharon Benzeno | Chief Commercial Officer of Immune Medicine | 0.14% |
| Peter Neupert | Lead Independent Director | 0.08% |
| Katey Owen | Independent Director | 0.04% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-04 | Julie Rubinstein | President | Derivative Exercise and Sale | -35,643 | $12.14–29.67 |
| 2026-09-30 | Julie Rubinstein | President | Intent to Sell (Form 144) | -379,777 | $28.90 |
| 2026-09-30 | Francis Lo | Chief Human Resources Officer | Derivative Exercise and Sale | -26,792 | $3.99–28.61 |
| 2026-09-15 | Francis Lo | Chief Human Resources Officer | Automatic Disposition | -9,846 | $28.02–28.57 |
| 2026-09-15 | Francis Lo | Chief Human Resources Officer | Derivative Exercise and Sale | -105,560 | $3.99–28.02 |
| 2026-09-14 | Susan Bobulsky | Senior Vice President of Diagnostics - ClonoSEQ | Automatic Disposition | -1,195 | $27.00 |
| 2026-08-30 | Katey Owen | Independent Director | Other Disposition | -12,539 | -- |
| 2026-08-25 | Katey Owen | Independent Director | Open Market Disposition | -9,615 | $26.00 |
| 2026-08-19 | Harlan Robins | Co-Founder & CSO | Intent to Sell (Form 144) | -402,160 | $25.44 |
| 2026-08-18 | Harlan Robins | Co-Founder & CSO | Intent to Sell (Form 144) | -215,632 | $25.49 |
| 2026-08-17 | Robert Hershberg | Independent Director | Open Market Disposition | -15,664 | $24.41 |
| 2026-08-17 | Robert Hershberg | Independent Director | Derivative Exercise and Sale | -15,000 | $6.32–24.39 |
| 2026-08-17 | Harlan Robins | Co-Founder & CSO | Intent to Sell (Form 144) | -261,044 | $24.56 |
| 2026-08-17 | Chad Robins | Chairperson & CEO | Derivative Exercise and Sale | -600,000 | $6.55–25.57 |
| 2026-08-17 | Chad Robins | Chairperson & CEO | Intent to Sell (Form 144) | -278,676 | $24.56 |
| 2026-08-16 | Peter Neupert | Lead Independent Director | Open Market Disposition | -109,690 | $25.10–25.16 |
| 2026-08-16 | Peter Neupert | Lead Independent Director | Derivative Exercise and Sale | -15,000 | $6.32–25.23 |
| 2026-08-16 | Harlan Robins | Co-Founder & CSO | Intent to Sell (Form 144) | -300,992 | $24.77 |
| 2026-08-16 | Chad Robins | Chairperson & CEO | Intent to Sell (Form 144) | -321,324 | $24.77 |
| 2026-08-09 | Susan Bobulsky | Senior Vice President of Diagnostics - ClonoSEQ | Automatic Disposition | -3,000 | $25.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:30:14 · For reference only, not investment advice and not tailored to your situation.